BDNF Otic Formulation Sustained Inner Ear Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inner ear diseases face challenges such as limited drug delivery due to isolation from the circulatory system, high systemic side effects, and discomfort from frequent intratympanic injections, which often result in osmotic imbalances and structural damage.
Innovation Solution
Development of otic formulations containing brain-derived neurotrophic factor (BDNF) in a thermoreversible auris-acceptable gel, providing sustained release into the inner ear to treat hearing loss and related conditions, with a composition that includes poloxamer 407 and is compatible with the inner ear's pH and osmolarity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intratympanic injections are administered frequently to treat inner ear diseases, then drug delivery to the inner ear is improved, but patient discomfort increases and osmotic imbalances occur
Solution Approach 1:
The patent employs a sustained-release formulation that continuously delivers BDNF to the inner ear over an extended period (at least 5 days, preferably 1 week or more), eliminating the need for frequent injections while maintaining reliable drug delivery. The formulation is designed to release the growth factor gradually, ensuring continuous therapeutic action without repeated patient visits or injections.
Solution Approach 2:
The patent uses an auris-acceptable vehicle as an intermediary carrier that facilitates sustained delivery of BDNF to the inner ear. This vehicle system acts as a mediator between the administered BDNF and the target tissue, enabling controlled release over time while avoiding direct repeated intratympanic injections that cause discomfort.
2Reliability
If intratympanic injections are administered to deliver drugs to the inner ear, then drug delivery is improved, but structural damage occurs due to osmotic imbalances
Solution Approach 1:
The patent carefully controls the osmolarity parameter of the formulation to match auris-acceptable conditions, preventing osmotic imbalances that cause structural damage. The formulation is designed with appropriate osmotic properties that are compatible with inner ear tissues, eliminating harmful effects while maintaining effective drug delivery.
Solution Approach 2:
The patent employs a single sustained-release formulation that provides extended treatment (at least 5 days or more), replacing multiple repeated injections. This single formulation approach eliminates repeated trauma to the tympanic membrane and inner ear structures, preventing cumulative structural damage while maintaining therapeutic effectiveness.
3Adaptability or versatility
If systemic administration is used to treat inner ear diseases, then treatment coverage is improved, but systemic side effects increase
Solution Approach 1:
The patent delivers BDNF locally to the inner ear through intratympanic administration with sustained release, concentrating the therapeutic effect at the target site. This localized delivery approach treats the specific inner ear condition without distributing the drug systemically, thereby avoiding systemic side effects while maintaining effective treatment coverage for the affected area.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The otic formulations achieve extended drug exposure, reducing systemic side effects and improving hearing function by repairing ribbon synapses and providing effective treatment for cochlear synaptopathy and hearing impairments without causing osmotic imbalances or structural damage.
Implementation Method 1
the auris-acceptable gel is a thermoreversible gel
Data Source
AI summary
Disclosed herein are otic formulations and compositions comprising BDNF. These otic formulations and compositions allow for the delivery of BDNF to the inner ear for the treatment of otic diseases and disorders.